HNRNPA2B1 Antibody

What is HNRNPA2B1 and why is it an important research target?

HNRNPA2B1 (heterogeneous nuclear ribonucleoprotein A2/B1) is a multifunctional protein primarily involved in mRNA processing and RNA splicing. In humans, the canonical protein has 353 amino acid residues with a molecular weight of approximately 37.4 kDa, and localizes to both the nucleus and cytoplasm . Alternative splicing generates two main isoforms: HNRNPA2 (36 kDa) and HNRNPB1 (38 kDa) . Beyond its canonical roles in RNA metabolism, HNRNPA2B1 participates in telomere maintenance, cell proliferation, differentiation, and glucose transport . More recently, it has been identified as an innate immune sensor that initiates type I interferon production during DNA virus infection . Its diverse functions make it a critical target for research in RNA biology, immunology, and disease pathogenesis.

What factors should be considered when selecting an HNRNPA2B1 antibody for my experiments?

When selecting an HNRNPA2B1 antibody, researchers should consider:

• Application compatibility: Ensure the antibody is validated for your specific application (WB, IHC, IF, IP, etc.) .

• Species reactivity: Verify cross-reactivity with your experimental species (human, mouse, rat, etc.) .

• Epitope specificity: Consider whether the antibody recognizes both isoforms (A2/B1) or is specific to one .

• Clonality: Monoclonal antibodies offer higher specificity for a single epitope while polyclonal antibodies may provide stronger signals by recognizing multiple epitopes .

• Validation data: Review available Western blot images or other validation data to ensure proper molecular weight detection .

• Knockout validation: Antibodies validated in knockout systems offer superior confirmation of specificity .

• Post-translational modification detection: If studying particular modifications (e.g., sumoylation), ensure the antibody detects the modified form .

What are the standard applications for HNRNPA2B1 antibodies in research?

HNRNPA2B1 antibodies can be utilized across multiple experimental applications:

• Western blotting (WB): Most frequently used to detect protein expression levels and molecular weight confirmation (36-38 kDa) .

• Immunohistochemistry (IHC): For examining HNRNPA2B1 expression in tissue sections and investigating subcellular localization patterns .

• Immunocytochemistry (ICC)/Immunofluorescence (IF): For visualizing protein distribution in cultured cells .

• Immunoprecipitation (IP): For isolating HNRNPA2B1 and its binding partners from cell lysates .

• Chromatin immunoprecipitation (ChIP): For investigating HNRNPA2B1 associations with chromatin .

• Co-immunoprecipitation (Co-IP): For studying protein-protein interactions involving HNRNPA2B1 .

• ELISA: For quantitative detection in appropriate sample types .

How can I optimize Western blotting protocols for HNRNPA2B1 detection?

For optimal HNRNPA2B1 detection via Western blotting:

• Sample preparation: Extract nuclear and cytoplasmic fractions separately to comprehensively assess HNRNPA2B1 distribution, as it localizes to both compartments .

• Protein loading: Load 20-40 μg of total protein per lane for cell lysates.

• Gel percentage: Use 10-12% SDS-PAGE gels for optimal resolution of the 36-38 kDa protein bands .

• Transfer conditions: Semi-dry or wet transfer at 100V for 60-90 minutes with methanol-containing buffer.

• Blocking: 5% non-fat milk or BSA in TBST for 1 hour at room temperature.

• Primary antibody dilution: Typically 1:1000-1:5000 dilution is appropriate, but verify manufacturer recommendations .

• Incubation time: Overnight at 4°C for primary antibody; 1-2 hours at room temperature for secondary antibody.

• Detection method: Both chemiluminescence and fluorescence-based methods work well.

• Expected bands: Look for bands at 36 kDa (HNRNPA2) and/or 38 kDa (HNRNPB1) depending on the cell/tissue type and antibody specificity .

• Positive controls: HeLa or HEK293 cell lysates typically show strong HNRNPA2B1 expression .

What are the critical steps for successful immunohistochemistry using HNRNPA2B1 antibodies?

For effective IHC with HNRNPA2B1 antibodies:

• Fixation: 10% neutral buffered formalin is standard, but paraformaldehyde may better preserve epitopes.

• Antigen retrieval: Heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) is generally effective .

• Blocking: Use 5-10% normal serum from the same species as the secondary antibody to minimize background.

• Primary antibody dilution: Use at 1:50-1:200 dilution as a starting point, then optimize .

• Incubation conditions: Overnight at 4°C typically yields best results for primary antibody.

• Detection system: Both HRP-DAB and fluorescent systems are suitable; choose based on microscopy availability.

• Expected staining pattern: Nuclear staining predominates in most tissues, with potential cytoplasmic staining depending on cell type .

• Controls: Include both positive controls (tissues known to express HNRNPA2B1) and negative controls (primary antibody omitted or isotype control).

• Counterstaining: Hematoxylin provides good nuclear contrast for brightfield microscopy.

• Multiplex considerations: When co-staining with other markers, be aware of potential cross-reactivity issues.

How can I differentiate between HNRNPA2 and HNRNPB1 isoforms in my experiments?

Differentiating between the two main isoforms requires specific experimental strategies:

• Isoform-specific antibodies: Some antibodies are specifically designed to recognize unique epitopes in either HNRNPA2 or HNRNPB1 .

• Western blot resolution: Use longer SDS-PAGE runs with 10-12% gels to clearly separate the 36 kDa (HNRNPA2) and 38 kDa (HNRNPB1) bands .

• 2D gel electrophoresis: Can separate isoforms based on both molecular weight and isoelectric point.

• Mass spectrometry: For definitive isoform identification after immunoprecipitation.

• RT-PCR with isoform-specific primers: To assess mRNA expression of each isoform.

• RNA interference: Design siRNAs targeting unique regions of each isoform to confirm antibody specificity.

What are the best methods for visualizing HNRNPA2B1 subcellular localization?

To accurately visualize HNRNPA2B1 subcellular distribution:

• Immunofluorescence optimizations:

  • Use 1:100-1:500 dilution for primary antibodies

  • Include nuclear counterstains (DAPI or Hoechst)

  • Consider nuclear export inhibitors (leptomycin B) to study nuclear retention

  • Use confocal microscopy for precise co-localization studies

• Nuclear vs. cytoplasmic extraction:

  • Commercial fractionation kits work well for biochemical separation

  • Western blot analysis of fractions can quantify distribution ratios

  • Include proper loading controls for each fraction (e.g., lamin for nuclear, GAPDH for cytoplasmic)

• Live-cell imaging options:

  • CRISPR-mediated tagging with fluorescent proteins

  • Transient transfection with fluorescently tagged HNRNPA2B1 constructs

• Environmental influences:

  • Document localization changes upon stress stimuli (heat shock, oxidative stress)

  • Monitor during viral infection when HNRNPA2B1 functions as an innate immune sensor

How is HNRNPA2B1 involved in innate immune responses, and how can antibodies help investigate this function?

HNRNPA2B1 plays crucial roles in innate immunity through several mechanisms:

• DNA virus sensing: HNRNPA2B1 functions as a nuclear sensor for DNA viruses, initiating type I interferon (IFN) production . Researchers can use antibodies in the following experimental approaches:

  • ChIP assays to detect HNRNPA2B1 binding to viral DNA

  • Co-IP experiments to identify virus-induced protein complexes

  • Western blotting to monitor HNRNPA2B1 expression changes during infection

• Post-translational modification dynamics: Upon HSV-1 infection, HNRNPA2B1 undergoes demethylation catalyzed by JMJD6, activating IFN-β expression . This can be studied using:

  • Methylation-specific antibodies

  • IP followed by mass spectrometry to identify modification sites

  • Co-IP to detect JMJD6-HNRNPA2B1 interactions during infection

• mRNA trafficking regulation: HNRNPA2B1 promotes N6-methyladenosine (m6A) modification and nucleocytoplasmic trafficking of CGAS, IFI16, and STING mRNAs . Researchers can investigate this using:

  • RNA-IP to isolate HNRNPA2B1-bound transcripts

  • m6A-seq with HNRNPA2B1 knockdown/knockout controls

  • Subcellular fractionation with RT-qPCR to measure target mRNA distribution

What role does HNRNPA2B1 play in disease contexts, and how can antibodies facilitate this research?

HNRNPA2B1 has been implicated in various disease processes:

• Cancer research applications:

  • IHC to evaluate expression in patient tumors versus normal tissues

  • Tissue microarray analysis to correlate expression with patient outcomes

  • Co-staining with proliferation markers to assess relationships with tumor growth

• Neurodegenerative disease investigations:

  • Detecting pathological aggregates in ALS and frontotemporal dementia models

  • Studying interactions with TDP-43 in disease models

  • Monitoring stress granule formation in response to cellular stressors

• Viral infection studies:

  • Tracking HNRNPA2B1 redistribution during different viral infections

  • Assessing post-translational modifications that regulate antiviral activity

  • Measuring interaction with viral components via co-IP or proximity ligation assays

How can post-translational modifications of HNRNPA2B1 be investigated using antibodies?

Post-translational modifications (PTMs) critically regulate HNRNPA2B1 function:

• Methylation studies:

  • Use methylation-specific antibodies to detect arginine methylation status

  • Monitor changes in methylation after JMJD6 manipulation

  • Employ IP followed by Western blotting with methyl-specific antibodies

• Sumoylation analysis:

  • IP with HNRNPA2B1 antibodies followed by SUMO detection

  • Use SUMO-specific antibodies for co-localization studies

  • Compare wild-type versus sumoylation-deficient mutants

• Phosphorylation mapping:

  • Phospho-specific antibodies for key regulatory sites

  • Phosphatase treatments to confirm specificity

  • IP followed by phospho-proteomic analysis

• Ubiquitination detection:

  • Co-IP with ubiquitin and HNRNPA2B1 antibodies

  • Proteasome inhibitor treatments to enhance detection

  • In vitro ubiquitination assays with recombinant components

How can I validate the specificity of my HNRNPA2B1 antibody?

Thorough validation is critical for reliable research outcomes:

• Knockout/knockdown controls:

  • Use CRISPR/Cas9 knockout cell lines for absolute validation

  • siRNA or shRNA knockdown for partial reduction of signal

  • Compare signal intensity between wild-type and depleted samples

• Peptide competition assays:

  • Pre-incubate antibody with immunizing peptide

  • Signal should be significantly reduced if antibody is specific

• Multiple antibody comparison:

  • Use antibodies targeting different epitopes of HNRNPA2B1

  • Consistent results across antibodies suggest higher specificity

• Recombinant protein controls:

  • Test antibody against purified recombinant HNRNPA2B1

  • Include both isoforms to assess cross-reactivity

• Cross-species reactivity:

  • Verify predicted cross-reactivity with samples from multiple species

  • Consider sequence homology when interpreting results

What are common issues when working with HNRNPA2B1 antibodies and how can they be resolved?

Researchers frequently encounter several challenges:

• Non-specific bands in Western blots:

  • Increase blocking time/concentration

  • Optimize primary antibody dilution (try 1:2000-1:5000)

  • Use gradient gels for better resolution of 36-38 kDa region

  • Consider using PVDF membranes for cleaner results

• Weak signal intensity:

  • Verify HNRNPA2B1 expression in your sample type

  • Increase protein loading (40-60 μg per lane)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Use signal enhancement systems compatible with your detection method

• High background in immunostaining:

  • Increase blocking time and concentration

  • Use more stringent washing conditions

  • Consider autofluorescence quenching for IF applications

  • Optimize antibody dilution (start with 1:100-1:200)

• Inconsistent results between applications:

  • Some antibodies perform better in certain applications

  • Fixation conditions can affect epitope accessibility

  • Consider using application-specific validated antibodies

How can I determine if my HNRNPA2B1 antibody detects both isoforms or is isoform-specific?

To ascertain isoform specificity:

• Analysis of known isoform-expressing samples:

  • Compare tissues/cell lines with different isoform expression profiles

  • Look for single versus double bands at 36 kDa and 38 kDa

• Recombinant protein testing:

  • Run Western blots with purified recombinant HNRNPA2 and HNRNPB1

  • Compare band positions and intensity

• Isoform-specific depletion:

  • Design isoform-specific siRNAs or CRISPR guides

  • Monitor selective disappearance of bands

• Epitope mapping:

  • Review antibody datasheets for epitope information

  • The first 12 amino acids of HNRNPB1 are absent in HNRNPA2, so antibodies targeting this region will be B1-specific

How can HNRNPA2B1 antibodies be utilized in RNA biology research?

HNRNPA2B1's central role in RNA metabolism offers several research applications:

• RNA immunoprecipitation (RIP) protocols:

  • Optimize crosslinking conditions (formaldehyde or UV)

  • Use stringent washes to reduce non-specific RNA binding

  • Consider CLIP-seq for higher resolution binding site identification

  • Compare wild-type versus RNA-binding mutants

• m6A epitranscriptomic studies:

  • Combine with m6A-specific antibodies for co-localization studies

  • Use m6A-seq with HNRNPA2B1 manipulation to identify regulated transcripts

  • Investigate interactions with m6A writers, readers, and erasers via co-IP

• Alternative splicing analysis:

  • RT-PCR with exon-spanning primers after HNRNPA2B1 depletion

  • RNA-seq to globally profile splicing changes

  • Minigene assays to directly test splicing regulation

What considerations are important when using HNRNPA2B1 antibodies in virus infection studies?

When investigating HNRNPA2B1's role during viral infection:

• Timing considerations:

  • Monitor HNRNPA2B1 localization and modification at multiple timepoints post-infection

  • Early timepoints (0-4 hours) capture initial sensing events

  • Later timepoints reveal feedback regulation

• Virus-specific protocols:

  • DNA viruses (HSV-1, adenovirus) trigger nuclear sensing pathways

  • RNA viruses may engage different HNRNPA2B1 functions

  • Compare responses across multiple virus families

• Downstream signaling assessment:

  • Co-stain for phosphorylated IRF3 to correlate with HNRNPA2B1 activation

  • Monitor IFN-β production via reporter assays or ELISA

  • Track STING, cGAS, and IFI16 protein levels in relation to HNRNPA2B1 activity

• Cell-type specific responses:

  • Compare primary cells versus cell lines

  • Assess differences between immune and non-immune cells

  • Consider tissue-specific regulation

What novel technologies are advancing HNRNPA2B1 research beyond traditional antibody applications?

Cutting-edge approaches are expanding research capabilities:

• CRISPR applications:

  • Endogenous tagging for live-cell imaging

  • Domain-specific mutagenesis to dissect function

  • CUT&RUN as an alternative to ChIP for genomic binding studies

• Proximity labeling techniques:

  • BioID or APEX2 fusions to identify transient interactors

  • Spatially-restricted labeling in specific subcellular compartments

  • Stimulus-dependent interaction networks

• Super-resolution microscopy:

  • STORM or PALM for nanoscale localization

  • Live-cell super-resolution to track dynamics

  • Correlative light and electron microscopy for ultrastructural context

• Single-cell approaches:

  • Single-cell Western blotting for heterogeneity analysis

  • scRNA-seq with HNRNPA2B1 perturbations

  • Multi-omics integration to connect HNRNPA2B1 activity with cellular outcomes